Nephrology Dialysis Transplantation, Vol 13, Issue 90007 30-32, Copyright © 1998 by Oxford University Press
N Mallick, A Olujohungbe and M Drayson
It is generally considered that a patient with myeloma who also has
established renal impairment is unlikely to do well. While this is
sometimes the case, analysis of recent data shows: (a) of 2768 patients in
the MRC database for the fourth to the sixth trials, 10/163 with serum
creatinine 300-600 &mgr;m/l and 20/89 with serum creatinine 600
&mgr;/l at presentation had renal failure as a recorded presenting
feature, whatever the renal function, the most common presenting feature
was bone pain; (b) that many patients have persisting evidence of reduced
renal function yet survive for more than the median time of 36 months which
applied to myeloma generally. Patients with renal impairment, especially
those whose myeloma is brought to plateau by chemotherapy, should be
assessed thoroughly for evidence of other than myeloma induced renal damage
as both renovascular disease and prostatic obstruction in males are common
in the elderly population at risk.
ORIGINAL ARTICLES
Renal impairment in myeloma: time for a reappraisal?
Department of Renal Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK; Corresponding author
![]()
CiteULike
Connotea
Del.icio.us What's this?